Advanced glycation end products inhibit the osteogenic differentiation potential of adipose‐derived stem cells by modulating Wnt/β‐catenin signalling pathway via DNA methylation
Cell Proliferation2020Vol. 53(6), pp. e12834–e12834
Citations Over TimeTop 10% of 2020 papers
Abstract
Advanced glycation end products inhibit the osteogenic differentiation ability of ASCs by activating DNA methylation and inhibiting Wnt/β-catenin pathway in vitro. Therefore, DNA methylation may be promising targets for the bone regeneration of ASCs with diabetic osteoporosis.
Related Papers
- → Uremic Toxicity of Advanced Glycation End Products in CKD(2015)229 cited
- Advanced glycation end product (AGE) modified proteins in tears of diabetic patients.(2010)
- → Identification of Nω-Carboxymethylarginine, a New Advanced Glycation Endproduct in Serum Proteins of Diabetic Patients: Possibility of a New Marker of Aging and Diabetes(2001)56 cited
- → Injury of cortical neurons is caused by the advanced glycation end products-mediated pathway.(2013)6 cited
- Advanced Glycation End Products and Its Receptor System and Diabetic Nephropathy(2009)